Multiple Myeloma
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
Original Research
In-Depth Look at a Community- Based Population of Multiple Myeloma (MM) Patients Undergoing an in-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib in the United States (US) MM-6 Study
Original Research
Effective Pain Control With Very Low Dose Palliative Radiotherapy for Multiple Myeloma Patients With Osseous Lesions
News
Transitioning regimen may prolong proteasome inhibitor–based therapy for MM
Transitioning from parenteral bortezomib-based induction to all-oral ixazomib-lenalidomide-dexamethasone increased PI-based treatment adherence/...
News
Vaccination regimen effective in preventing pneumonia in MM patients
News
ASH tackles COVID-19 with hematology-related FAQ, promotes new registries
News
First report of MM patient successfully treated for COVID-19 with tocilizumab
The patient presented with chest tightness and shortness of breath, indicating that symptoms of COVID-19 can be atypical in patients with...
News
Maintaining cancer care in the face of COVID-19
Oncologists are moving cancer patients to other hospitals, reevaluating the need for cancer treatments, and embracing telemedicine to protect...
Conference Coverage
Stored CD34 cells for multiple myeloma patients largely unused
ORLANDO –
News
New CAR T-cell therapy eliminates MM and tumor propagating cells without fratricide in lab study
CD229 CAR T cells are highly active in vitro and in vivo against multiple myeloma plasma cells, memory B cells, and MM-propagating cells.